MBVX Stock DD MabVax Therapeutics Holdings, Inc. 11/20/2014 22:14:26

Message Board

Previous

| Next

Post# of 250663

Posted On: 11/20/2014 11:14:25 PM

Posted By: Rosner

MBVX MabVax Therapeutics Holdings, Inc. $MBVX Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=MBVX&...mp;yt0=Go!

Last Updated: 11/20/2014 22:14:22

Current Price and Quotes
Last Price 3.00
Previous Close 3.10 Open 3.00
Daily Range 3.00 - 3.00 52wk Range 1.01 - 16.48
Volume 5,263 Dividend N/A
Average Vol (30d) 1,528 Yield N/A

Financials

Recent News
Source
Nov 19, 2014 MabVax Therapeutics And Memorial Sloan-Kettering Cancer Center Report on Potential Use of Dual-Labeled Antibody To Detect and Guide Surgical Removal of Pancreatic Cancer PR NEWSWIRE
Nov 17, 2014 MabVax Is Under The Radar, But Undervalued: CEO David Hansen Seeking Alpha
Oct 23, 2014 MabVax Therapeutics - &quot;Introducing MabVax Therapeutics: Newly Public Company Achieves Multiple Milestones in Recent Quarter&quot; ACCESSWIRE
Oct 23, 2014 MabVax Therapeutics Launches Online Corporate Communication Channels and New Website PR NEWSWIRE
Oct 21, 2014 MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company's Lead Clinical Development Candidate PR NEWSWIRE
Oct 10, 2014 MabVax Therapeutics Announces Stock Ticker Symbol Change to MBVX PR NEWSWIRE
Sep 25, 2014 MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma PR NEWSWIRE
Sep 10, 2014 MabVax Therapeutics Enters Agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Development of Anti-Cancer Therapeutics PR NEWSWIRE
Sep 9, 2014 MabVax Therapeutics Receives Stockholder Approval for Name Change and Reverse Stock Split Resulting From Merger With Telik PR NEWSWIRE
Aug 28, 2014 Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers PR NEWSWIRE

1
2
next >

(0)

(0)